Bhardwaj Lab

Laboratory of Dr. Nina Bhardwaj🔬
@TischCancer @SinaiImmunol
Immunology & Immunotherapy
Posts by Lab Members

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Bhardwaj Lab @BhardwajLab]

Huge congratulations to @michelle_a_tran on graduating!🎓
The Bhardwaj lab team loved celebrating your incredible hard work and achievements over dinner. We are so proud of you and can't wait to see what you do next!✨
Cheers to the next chapter!🥂
#LabFamily #Graduation

[Nature Biotechnology @NatureBiotech]

Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models https://t.co/UKSLzrSmeP

[Bhardwaj Lab @BhardwajLab]

Trading pipettes for axes! Lab bonding last week was a 10/10 vibe. Looking at the lineup, who do you think lowkey had the best aim?🎯

[Bhardwaj Lab @BhardwajLab]

Huge congratulations to Michelle on officially finishing her MD-PhD. It’s been an incredible journey watching her balance the bench and the clinic with such dedication. We couldn’t be prouder of everything she’s accomplished. Cheers to Dr. Michelle!🥂 ##MDPhD #Graduation

[Mount Sinai Tisch Cancer Center @TischCancer]

Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer: Cell Reports Medicine https://t.co/mBrleYPEFJ
@BhardwajLab @IcahnMountSinai

[Bhardwaj Lab @BhardwajLab]

Huge congratulations to Michelle! So proud to see you graduate!

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

At the Icahn School of Medicine at Mount Sinai’s 2026 Commencement, our MD, PhD, and dual-degree graduates marked the culmination of years of dedication, discovery, and purpose.

With inspiring words from student speakers and the support of family, friends, and mentors, the evening reflected the passion and perseverance that define this class.

As these incredible individuals step into their next chapter, our graduates carry forward a commitment to advancing medicine, science, and compassionate care.

Congratulations to the Class of 2026.

[Bhardwaj Lab @BhardwajLab]

@TischCancer @SinaiImmunol #CancerResearch #Immunology #TumorImmunology

[Bhardwaj Lab @BhardwajLab]

Guillaume’s latest paper went online yesterday @CellRepMed! This research shows that a quad-blockade overcomes immune resistance in colorectal cancer by reprogramming macrophage-T cell crosstalk to induce high rates of tumor clearance. Check it out here: https://t.co/xpneceihJl

[Bhardwaj Lab @BhardwajLab]

Enjoy this little cartoon summarizing Guillaume's latest work in Cell Reports Medicine! https://t.co/xpneceihJl

[Nature Biotechnology @NatureBiotech]

mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression https://t.co/HCQVKRQxJU

[Bhardwaj Lab @BhardwajLab]

We are thrilled to share our latest work uncovering how the SPP1+ macrophage-driven inflammatory axis fuels immune evasion in bladder cancer. Fantastic job by Michelle and all our collaborators! 👏

[Cancer Discovery @CD_AACR]

Now online: A Tumor-Promoting Inflammatory SPP1 + Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer https://t.co/hr09gBoiKy

[Parker Institute for Cancer Immunotherapy @parkerici]

A year after NIH funding cuts, 27% of researchers report their funding hasn’t been restored. This is not just budgets; it is the future of science, and the impact is already being felt, as @cassiemcgrath_ reports in @HealthcareBrew.

As PICI CEO @DrKarenKnudsen shared with Healthcare Brew, these funding cuts have a large impact on researchers and patients, and stall bold innovative science. PICI is working to keep progress moving by backing high-risk, high-reward science and accelerating collaboration to turn all cancers into curable diseases.

Read Cassie’s full piece here: https://t.co/WAqRKONia4

[ACIR @ACIR_org]

Nie, Liu, Song, and Yao et al. developed a spleen delivery platform of mRNA-loaded lipid nanoparticles (LNPs) covalently bound to erythrocytes (mRNA-LNP-Ery), which naturally target splenic CD11b+ myeloid cells. Unlike conventional LNPs, mRNA-LNP-Ery entered cells via phagocytosis, avoiding lysosomal degradation and efficiently delivering mRNA. CAR myeloid cells (HER2 or CD19) adopted a proinflammatory antigen-presenting phenotype, migrated to tumors, and stimulated T and NK cell influx, potent antitumor activity, and systemic immunity, which was spleen-dependent. Repeated doses of mRNA-LNP-Ery resulted in superior efficacy at 1/10 the dose of LNPs. https://t.co/TArRajHZig

[nature @Nature]

Nature research paper: mRNA vaccines engage unconventional pathways in CD8+ T cell priming

https://t.co/DlxhSAmMlE

[Idoyaga Lab @Idoyaga_Lab]

⏳ 2 days left!
Abstract submission for #DC2026 closes April 17
🌍 Join the global DC community in San Diego
Submit your work now — don’t miss it!
https://t.co/INzFBL1xJH
@MaxKrummel @ZunigaLab 🔁

[Bhardwaj Lab @BhardwajLab]

Dr. Nina Bhardwaj will be at #AACR26! Looking forward to connecting, engaging, and discussing the latest in cancer immunology @AACR

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC review: "Bright side of the dark genome: antigens for next-gen cancer vaccines" https://t.co/pygy2eqLjU
@BernardAFox

[Roberto Vendramin @RobertVendramin]

🚨Paper alert🚨 Very excited to share our manuscript, published today in @ImmunityCP, where we describe how ‘Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome’. (1/16) https://t.co/S58jZLKZ7G

[Mount Sinai Tisch Cancer Center @TischCancer]

Jonathan Anker, MD, PhD, highlights response-guided bladder preservation stra... https://t.co/KS49LiHaRW via @YouTube
#bladdercancer @IcahnMountSinai